Sandra Horning speaks at an Endpoints News event during the #JPM19 healthcare conference (Jeff Rumans for Endpoints News)
September 6, 2019 06:41 AM EDT
R&D
Pharma

Roche boosts can­cer ap­provals in Eu­rope, push­ing for a big­ger slice of the I/O pie

Natalie Grover

Reporter

Roche is stack­ing up ap­provals for its flag­ship check­point in­hibitor in the lu­cra­tive field of lung can­cer. On Fri­day, the Swiss drug­mak­er re­vealed that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times